Foundry NetEqFin Industry-Neutral Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1NVDA | NVIDIA CORP | Technology | $4.91T | 22.12% |
2AAPL | APPLE INC | Technology | $4.90T | 22.10% |
3AVGO | BROADCOM INC | Technology | $1.76T | 7.95% |
4LLY | ELI LILLY & CO | Healthcare | $1.11T | 5.01% |
5V | VISA INC | Financial Services | $652.82B | 2.94% |
6JNJ | JOHNSON & JOHNSON | Healthcare | $609.12B | 2.75% |
7MA | MASTERCARD INC | Financial Services | $480.32B | 2.17% |
8ABBV | ABBVIE INC | Healthcare | $449.63B | 2.03% |
9AMAT | APPLIED MATERIALS INC | Technology | $420.53B | 1.90% |
10LRCX | LAM RESEARCH CORP | Technology | $391.80B | 1.77% |
11GE | GE AEROSPACE | Industrials | $361.93B | 1.63% |
12MRK | MERCK & CO INC | Healthcare | $314.90B | 1.42% |
13GEV | GE VERNOVA INC | Utilities | $284.26B | 1.28% |
14KLAC | KLA CORP | Technology | $277.91B | 1.25% |
15TXN | TEXAS INSTRUMENTS INC | Technology | $258.48B | 1.17% |
16AMGN | AMGEN INC | Healthcare | $197.69B | 0.89% |
17ADI | ANALOG DEVICES INC | Technology | $182.83B | 0.82% |
18QCOM | QUALCOMM INC | Technology | $181.06B | 0.82% |
19ABT | ABBOTT LABORATORIES | Healthcare | $175.37B | 0.79% |
20GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 0.75% |
21PFE | PFIZER INC | Healthcare | $142.77B | 0.64% |
22APP | APPLOVIN CORP | Technology | $142.62B | 0.64% |
23SCCO | SOUTHERN COPPER CORP | Basic Materials | $142.48B | 0.64% |
24BKNG | BOOKING HOLDINGS INC | Industrials | $140.78B | 0.63% |
25CRM | SALESFORCE INC | Technology | $139.86B | 0.63% |
26BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 0.56% |
27VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 0.56% |
28ISRG | INTUITIVE SURGICAL INC | Healthcare | $122.33B | 0.55% |
29FTNT | FORTINET INC | Technology | $118.40B | 0.53% |
30LMT | LOCKHEED MARTIN CORP | Industrials | $117.30B | 0.53% |
31NEM | NEWMONT CORP | Basic Materials | $95.76B | 0.43% |
32ADBE | ADOBE INC | Technology | $94.31B | 0.43% |
33MCO | MOODYS CORP | Financial Services | $89.25B | 0.40% |
34FCX | FREEPORT-MCMORAN INC | Basic Materials | $83.92B | 0.38% |
35MMM | 3M CO | Industrials | $83.37B | 0.38% |
36HCA | HCA HEALTHCARE INC | Healthcare | $82.34B | 0.37% |
37ITW | ILLINOIS TOOL WORKS INC | Industrials | $79.42B | 0.36% |
38EMR | EMERSON ELECTRIC CO | Industrials | $78.14B | 0.35% |
39REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 0.32% |
40TDG | TRANSDIGM GROUP INC | Industrials | $67.93B | 0.31% |
41AME | AMETEK INC | Industrials | $54.32B | 0.24% |
42CIEN | CIENA CORP | Technology | $53.00B | 0.24% |
43EW | EDWARDS LIFESCIENCES CORP | Healthcare | $49.36B | 0.22% |
44MSCI | MSCI INC | Financial Services | $45.77B | 0.21% |
45IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 0.20% |
46CMG | CHIPOTLE MEXICAN GRILL INC | Consumer Cyclical | $44.18B | 0.20% |
47BDX | BECTON DICKINSON & CO | Healthcare | $43.58B | 0.20% |
48VMC | VULCAN MATERIALS CO | Basic Materials | $37.41B | 0.17% |
49TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 0.17% |
50WDAY | WORKDAY INC | Technology | $35.76B | 0.16% |
51ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 0.16% |
52ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 0.16% |
53ON | ON SEMICONDUCTOR CORP | Technology | $34.24B | 0.15% |
54MLM | MARTIN MARIETTA MATERIALS INC | Basic Materials | $33.78B | 0.15% |
55RPRX | ROYALTY PHARMA PLC | Healthcare | $33.50B | 0.15% |
56UI | UBIQUITI INC | Technology | $33.04B | 0.15% |
57ZTS | ZOETIS INC | Healthcare | $32.10B | 0.14% |
58BIIB | BIOGEN INC | Healthcare | $30.41B | 0.14% |
59DXCM | DEXCOM INC | Healthcare | $29.58B | 0.13% |
60FICO | FAIR ISAAC CORP | Technology | $29.15B | 0.13% |
61RMD | RESMED INC | Healthcare | $28.86B | 0.13% |
62OTIS | OTIS WORLDWIDE CORP | Industrials | $28.18B | 0.13% |
63WSM | WILLIAMS SONOMA INC | Consumer Cyclical | $26.89B | 0.12% |
64MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $26.47B | 0.12% |
65VRSK | VERISK ANALYTICS INC | Industrials | $26.29B | 0.12% |
66VRSN | VERISIGN INC | Technology | $25.27B | 0.11% |
67ROIV | ROIVANT SCIENCES LTD | Healthcare | $24.82B | 0.11% |
68MRNA | MODERNA INC | Healthcare | $24.53B | 0.11% |
69EXPD | EXPEDITORS INTERNATIONAL OF WASHINGTON INC | Industrials | $23.91B | 0.11% |
70TEAM | ATLASSIAN CORP | Technology | $23.67B | 0.11% |
71WWD | WOODWARD INC | Industrials | $23.41B | 0.11% |
72UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.10% |
73VTRS | VIATRIS INC | Healthcare | $20.14B | 0.09% |
74FTV | FORTIVE CORP | Technology | $18.83B | 0.08% |
75NVR | NVR INC | Consumer Cyclical | $17.52B | 0.08% |
76NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.08% |
77LSCC | LATTICE SEMICONDUCTOR CORP | Technology | $17.16B | 0.08% |
78BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.94B | 0.07% |
79JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.53B | 0.07% |
80MEDP | MEDPACE HOLDINGS INC | Healthcare | $15.36B | 0.07% |
81CDE | COEUR MINING INC | Basic Materials | $14.85B | 0.07% |
82DECK | DECKERS OUTDOOR CORP | Consumer Cyclical | $14.79B | 0.07% |
83LOGI | LOGITECH INTERNATIONAL SA | Technology | $14.76B | 0.07% |
84EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.06% |
85CSL | CARLISLE COMPANIES INC | Basic Materials | $13.98B | 0.06% |
86EVR | EVERCORE INC | Financial Services | $13.21B | 0.06% |
87PINS | PINTEREST INC | Communication Services | $13.00B | 0.06% |
88ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $12.90B | 0.06% |
89MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $12.76B | 0.06% |
90DKNG | DRAFTKINGS INC | Consumer Cyclical | $12.37B | 0.06% |
91COKE | COCA-COLA CONSOLIDATED INC | Consumer Defensive | $12.03B | 0.05% |
92SEIC | SEI INVESTMENTS CO | Financial Services | $11.94B | 0.05% |
93BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $11.52B | 0.05% |
94PODD | INSULET CORP | Healthcare | $11.36B | 0.05% |
95TECH | BIO-TECHNE CORP | Healthcare | $11.29B | 0.05% |
96CART | INSTACART (MAPLEBEAR INC) | Consumer Cyclical | $10.77B | 0.05% |
97DPZ | DOMINOS PIZZA INC | Consumer Cyclical | $10.72B | 0.05% |
98KRYS | KRYSTAL BIOTECH INC | Healthcare | $10.46B | 0.05% |
99DOCU | DOCUSIGN INC | Technology | $10.07B | 0.05% |
100AYI | ACUITY INC (DE) | Industrials | $9.99B | 0.05% |
101CYTK | CYTOKINETICS INC | Healthcare | $9.98B | 0.04% |
102CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.04% |
103MANH | MANHATTAN ASSOCIATES INC | Technology | $9.66B | 0.04% |
104IT | GARTNER INC | Technology | $9.39B | 0.04% |
105HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.04% |
106PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $9.06B | 0.04% |
107IONS | IONIS PHARMACEUTICALS INC | Healthcare | $8.99B | 0.04% |
108SWKS | SKYWORKS SOLUTIONS INC | Technology | $8.93B | 0.04% |
109ALKS | ALKERMES PLC | Healthcare | $8.79B | 0.04% |
110TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 0.04% |
111RGEN | REPLIGEN CORP | Healthcare | $8.31B | 0.04% |
112ETSY | ETSY INC | Consumer Cyclical | $7.98B | 0.04% |
113DBX | DROPBOX INC | Technology | $7.14B | 0.03% |
114PAYC | PAYCOM SOFTWARE INC | Technology | $7.05B | 0.03% |
115LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 0.03% |
116CRUS | CIRRUS LOGIC INC | Technology | $6.98B | 0.03% |
117PPC | PILGRIMS PRIDE CORP | Consumer Defensive | $6.93B | 0.03% |
118RIOT | RIOT PLATFORMS INC | Financial Services | $6.91B | 0.03% |
119CHE | CHEMED CORP | Healthcare | $6.77B | 0.03% |
120MSA | MSA SAFETY INC | Industrials | $6.60B | 0.03% |
121MORN | MORNINGSTAR INC | Financial Services | $6.56B | 0.03% |
122PTCT | PTC THERAPEUTICS INC | Healthcare | $6.52B | 0.03% |
123APPF | APPFOLIO INC | Technology | $6.36B | 0.03% |
124CVLT | COMMVAULT SYSTEMS INC | Technology | $6.10B | 0.03% |
125LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.08B | 0.03% |
126TWST | TWIST BIOSCIENCE CORP | Healthcare | $5.84B | 0.03% |
127AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $5.69B | 0.03% |
128DAVE | DAVE INC | Technology | $5.60B | 0.03% |
129PEGA | PEGASYSTEMS INC | Technology | $5.39B | 0.02% |
130MC | MOELIS & CO | Financial Services | $5.30B | 0.02% |
131TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.02% |
132KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.02% |
133FCN | FTI CONSULTING INC | Industrials | $4.90B | 0.02% |
134FELE | FRANKLIN ELECTRIC CO INC | Industrials | $4.67B | 0.02% |
135KNF | KNIFE RIVER CORP | Basic Materials | $4.64B | 0.02% |
136FHI | FEDERATED HERMES INC | Financial Services | $4.46B | 0.02% |
137MDU | MDU RESOURCES GROUP INC | Industrials | $4.42B | 0.02% |
138ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.02% |
139CNS | COHEN & STEERS INC | Financial Services | $4.35B | 0.02% |
140EXLS | EXLSERVICE HOLDINGS INC | Technology | $4.30B | 0.02% |
141BOX | BOX INC | Technology | $4.22B | 0.02% |
142CALM | CAL-MAINE FOODS INC | Consumer Defensive | $4.20B | 0.02% |
143PLNT | PLANET FITNESS INC | Consumer Cyclical | $4.16B | 0.02% |
144MKTX | MARKETAXESS HOLDINGS INC | Financial Services | $4.04B | 0.02% |
145DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.02% |
146POWI | POWER INTEGRATIONS INC | Technology | $3.93B | 0.02% |
147WING | WINGSTOP INC | Consumer Cyclical | $3.88B | 0.02% |
148YETI | YETI HOLDINGS INC | Consumer Cyclical | $3.87B | 0.02% |
149CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.02% |
150OLED | UNIVERSAL DISPLAY CORP | Technology | $3.75B | 0.02% |
151LOPE | GRAND CANYON EDUCATION INC | Consumer Defensive | $3.72B | 0.02% |
152ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $3.67B | 0.02% |
153ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.56B | 0.02% |
154OGN | ORGANON & CO | Healthcare | $3.55B | 0.02% |
155AB | ALLIANCEBERNSTEIN HOLDING LP | Financial Services | $3.54B | 0.02% |
156HAE | HAEMONETICS CORP | Healthcare | $3.54B | 0.02% |
157RNG | RINGCENTRAL INC | Technology | $3.46B | 0.02% |
158BSM | BLACK STONE MINERALS LP | Energy | $3.25B | 0.01% |
159IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 0.01% |
160CARG | CARGURUS INC | Consumer Cyclical | $3.16B | 0.01% |
161EXPO | EXPONENT INC | Industrials | $3.05B | 0.01% |
162AD | ARRAY DIGITAL INFRASTRUCTURE INC | Communication Services | $3.02B | 0.01% |
163USLM | UNITED STATES LIME & MINERALS INC | Basic Materials | $3.01B | 0.01% |
164RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 0.01% |
165BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.83B | 0.01% |
166SUPN | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.79B | 0.01% |
167CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.77B | 0.01% |
168APAM | ARTISAN PARTNERS ASSET MANAGEMENT INC | Financial Services | $2.73B | 0.01% |
169GRND | GRINDR INC | Technology | $2.71B | 0.01% |
170TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $2.58B | 0.01% |
171PBI | PITNEY BOWES INC | Industrials | $2.51B | 0.01% |
172PGNY | PROGYNY INC | Healthcare | $2.50B | 0.01% |
173VCEL | VERICEL CORP | Healthcare | $2.38B | 0.01% |
174PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.36B | 0.01% |
175BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.01% |
176AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $2.36B | 0.01% |
177INTA | INTAPP INC | Technology | $2.24B | 0.01% |
178NEOG | NEOGEN CORP | Healthcare | $2.24B | 0.01% |
179SION | SIONNA THERAPEUTICS INC | Healthcare | $2.23B | 0.01% |
180BKE | BUCKLE INC | Consumer Cyclical | $2.19B | 0.01% |
181SPB | SPECTRUM BRANDS HOLDINGS INC | Consumer Defensive | $2.06B | 0.01% |
182AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.01% |
183CDNA | CAREDX INC | Healthcare | $2.05B | 0.01% |
184NUVB | NUVATION BIO INC | Healthcare | $2.03B | 0.01% |
185SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $2.02B | 0.01% |
186ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.01% |
187ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $1.97B | 0.01% |
188HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.01% |
189MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.01% |
190SAM | BOSTON BEER CO INC | Consumer Defensive | $1.86B | 0.01% |
191MQ | MARQETA INC | Technology | $1.85B | 0.01% |
192SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.01% |
193ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.80B | 0.01% |
194IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 0.01% |
195ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.01% |
196AESI | ATLAS ENERGY SOLUTIONS INC | Energy | $1.76B | 0.01% |
197HROW | HARROW INC | Healthcare | $1.74B | 0.01% |
198ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.01% |
199INVA | INNOVIVA INC | Healthcare | $1.60B | 0.01% |
200XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $1.52B | 0.01% |
201SEPN | SEPTERNA INC | Healthcare | $1.51B | 0.01% |
202PRGO | PERRIGO CO PLC | Healthcare | $1.48B | 0.01% |
203INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.01% |
204YELP | YELP INC | Communication Services | $1.44B | 0.01% |
205BRBR | BELLRING BRANDS INC | Consumer Defensive | $1.41B | 0.01% |
206ENR | ENERGIZER HOLDINGS INC | Industrials | $1.39B | 0.01% |
207CXM | SPRINKLR INC | Technology | $1.37B | 0.01% |
208PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.01% |
209NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.01% |
210LZ | LEGALZOOMCOM INC | Industrials | $1.33B | 0.01% |
211HLIT | HARMONIC INC | Technology | $1.31B | 0.01% |
212XNCR | XENCOR INC | Healthcare | $1.30B | 0.01% |
213NSSC | NAPCO SECURITY TECHNOLOGIES INC | Industrials | $1.29B | 0.01% |
214ARDX | ARDELYX INC | Healthcare | $1.28B | 0.01% |
215INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.01% |
216DFIN | DONNELLEY FINANCIAL SOLUTIONS INC | Financial Services | $1.25B | 0.01% |
217IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.01% |
218CMP | COMPASS MINERALS INTERNATIONAL INC | Basic Materials | $1.24B | 0.01% |
219QDEL | QUIDELORTHO CORP | Healthcare | $1.19B | 0.01% |
220COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.01% |
221ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.01% |
222MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.01% |
223SDGR | SCHRODINGER INC | Healthcare | $1.14B | 0.01% |
224CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $1.09B | 0.00% |
225PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.00% |
226JANX | JANUX THERAPEUTICS INC | Healthcare | $992M | 0.00% |
227MUX | MCEWEN INC | Basic Materials | $978M | 0.00% |
228KURA | KURA ONCOLOGY INC | Healthcare | $964M | 0.00% |
229TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.00% |
230AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $871M | 0.00% |
231NPK | NATIONAL PRESTO INDUSTRIES INC | Industrials | $870M | 0.00% |
232CYRX | CRYOPORT INC | Industrials | $832M | 0.00% |
233PD | PAGERDUTY INC | Technology | $794M | 0.00% |
234RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.00% |
235IBTA | IBOTTA INC | Technology | $734M | 0.00% |
236CLYM | CLIMB BIO INC | Healthcare | $727M | 0.00% |
237SPRY | ARS PHARMACEUTICALS INC | Healthcare | $695M | 0.00% |
238SWBI | SMITH & WESSON BRANDS INC | Industrials | $665M | 0.00% |
239CNNE | CANNAE HOLDINGS INC | Consumer Cyclical | $657M | 0.00% |
240TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.00% |
241TECX | TECTONIC THERAPEUTIC INC | Healthcare | $615M | 0.00% |
242NRDS | NERDWALLET INC | Communication Services | $609M | 0.00% |
243RGR | STURM RUGER & CO INC | Industrials | $604M | 0.00% |
244MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.00% |
245YEXT | YEXT INC | Technology | $535M | 0.00% |
246TASK | TASKUS INC | Technology | $534M | 0.00% |
247ARVN | ARVINAS INC | Healthcare | $517M | 0.00% |
248DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $517M | 0.00% |
249RGNX | REGENXBIO INC | Healthcare | $511M | 0.00% |
250XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.00% |
251NRC | NRC HEALTH | Healthcare | $491M | 0.00% |
252SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $479M | 0.00% |
253IPI | INTREPID POTASH INC | Basic Materials | $459M | 0.00% |
254PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.00% |
255TMS | TMS INTERNATIONAL CORP | Basic Materials | $451M | 0.00% |
256PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.00% |
257NVEC | NVE CORP | Technology | $418M | 0.00% |
258USNA | USANA HEALTH SCIENCES INC | Consumer Defensive | $403M | 0.00% |
259EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.00% |
260NATH | NATHANS FAMOUS INC | Consumer Cyclical | $393M | 0.00% |
261UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.00% |
262EOLS | EVOLUS INC | Healthcare | $377M | 0.00% |
263ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.00% |
264NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $359M | 0.00% |
265ELMD | ELECTROMED INC | Healthcare | $349M | 0.00% |
266VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.00% |
267MSB | MESABI TRUST | Basic Materials | $320M | 0.00% |
268LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.00% |
269TKNO | ALPHA TEKNOVA INC | Healthcare | $291M | 0.00% |
270TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.00% |
271HCKT | HACKETT GROUP INC | Technology | $261M | 0.00% |
272RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.00% |
273ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.00% |
274UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $222M | 0.00% |
275ANIK | ANIKA THERAPEUTICS INC | Healthcare | $203M | 0.00% |
276INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.00% |
277AOUT | AMERICAN OUTDOOR BRANDS INC | Industrials | $174M | 0.00% |
278ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.00% |
279AARD | AARDVARK THERAPEUTICS INC | Healthcare | $128M | 0.00% |
280JYNT | JOINT CORP | Healthcare | $127M | 0.00% |
281SAMG | SILVERCREST ASSET MANAGEMENT GROUP INC | Financial Services | $118M | 0.00% |
282FTLF | FITLIFE BRANDS INC | Consumer Defensive | $104M | 0.00% |
283CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $103M | 0.00% |
284ICCC | IMMUCELL CORP | Healthcare | $101M | 0.00% |
285RLYB | RALLYBIO CORP | Healthcare | $87M | 0.00% |
286CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.00% |
287LFVN | LIFEVANTAGE CORP | Consumer Defensive | $78M | 0.00% |
288BGSF | BGSF INC | Industrials | $65M | 0.00% |
289IMA | IMAGENEBIO INC | Healthcare | $61M | 0.00% |
290EURK | EUREKA ACQUISITION CORP | Industrials | $60M | 0.00% |
291CAPN | CAYSON ACQUISITION CORP | Industrials | $59M | 0.00% |
292EXOZ | EXOZYMES INC | Healthcare | $51M | 0.00% |
293TIL | INSTIL BIO INC | Healthcare | $50M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $22.18T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 87% toward Growth. +1% unclassified (22 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 293 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual62.8%Margin-12.2%The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Required<= 25.0%Actual35.5%Margin-10.5%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 293 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 33.1% | 27.0% |
| 3 yearsp.a. | 26.1% | 3.4% |
| 5 yearsp.a. | 18.5% | 17.5% |
| 10 yearsp.a. | 19.5% | 6.2% |
| Since inceptionp.a. | 10.8% | 1.8% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 11.2% | 11.2% |
| 2025 | 27.2% | -6.4% |
| 2024 | 37.1% | 6.3% |
| 2023 | 38.5% | 7.8% |
| 2022 | -21.3% | 40.0% |
| 2021 | 30.4% | 55.3% |
| 2020 | 27.7% | -45.7% |
| 2019 | 34.4% | 8.0% |
| 2018 | -0.0% | 14.9% |
| 2017 | 25.9% | 2.9% |
| 2016 | 5.8% | 4.5% |
| 2015 | 4.4% | 10.2% |
| 2014 | 19.4% | 12.2% |
| 2013 | 34.7% | -7.1% |
| 2012 | 12.0% | -0.6% |
| 2011 | 8.6% | 7.6% |
| 2010 | 9.1% | -10.3% |
| 2009 | 23.6% | -14.6% |
| 2008 | -24.4% | 48.0% |
| 2007 | 10.0% | 3.1% |
| 2006 | 13.6% | -0.5% |
| 2005 | 3.3% | -13.8% |
| 2004 | 3.4% | -15.4% |
| 2003 | 24.0% | -12.4% |
| 2002 | -22.7% | 13.7% |
| 2001 | -3.4% | 33.6% |
| 2000 | -9.3% | 25.9% |
| 1999 | 16.0% | -50.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry NetEqFin Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a NetEqFin signal and holds the top decile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.